Analgesic nephropathy in Canada: clinical syndrome, management, and outcome.
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects; D002110:Caffeine / Q000009:adverse effects; D002170:Canada; D003061:Codeine / Q000009:adverse effects; D003404:Creatinine / Q000097:blood; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008875:Middle Aged; D004366:Nonprescription Drugs; D010615:Phenacetin / Q000009:adverse effects; D019966:Substance-Related Disorders
D000700:Analgesics; D004338:Drug Combinations; D004366:Nonprescription Drugs; D002110:Caffeine; D003404:Creatinine; D010615:Phenacetin; D001241:Aspirin; D003061:Codeine